Education
About Us
Working with TipRanks
Follow Us
Illumina (ILMN)
NASDAQ:ILMN
ILMN Stock Chart & Stats
$141.65
-$1.43(-1.02%)
At close: 4:00 PM EST
$141.65
-$1.43(-1.02%)
Day’s Range― - ―
52-Week Range$68.70 - $151.34
Previous CloseN/A
Volume388.94K
Average Volume (3M)1.56M
Market Cap
$22.20B
Enterprise Value$15.42B
Total Cash (Recent Filing)$1.28B
Total Debt (Recent Filing)$2.58B
Price to Earnings (P/E)31.7
Beta1.25
Next Earnings
Feb 05, 2026EPS Estimate
1.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.34
Shares Outstanding152,800,000
10 Day Avg. Volume1,764,099
30 Day Avg. Volume1,562,893
Financial Highlights & Ratios
PEG Ratio-3.75
Price to Book (P/B)8.95
Price to Sales (P/S)4.86
P/FCF Ratio29.95
Enterprise Value/Market Cap0.69
Enterprise Value/Revenue3.60
Enterprise Value/Gross Profit5.43
Enterprise Value/Ebitda11.91
Forecast
1Y Price Target
$124.12Price Target Upside-12.38% Downside
Rating ConsensusHold
Number of Analyst Covering13
EPS Forecast (FY)5.06
Revenue Forecast (FY)$4.40B
Bulls Say, Bears Say
Bulls Say
China Market Re-entryAnalyst highlights that lifting of export restrictions restores the company's ability to export instruments to China, enabling reengagement with a previously restricted market and potential recovery of lost sales.
Clinical Consumables GrowthAnalyst notes accelerating clinical consumables demand as clinical customers adopt higher-throughput sequencing, supporting more sustainable consumables revenue growth.
High-throughput Platform AdoptionAnalyst reports that the company has largely completed its transition to the NovaSeq X high-throughput platform, which should boost throughput and support stronger instrument and consumable pull-through.
Bears Say
Backlog Conversion RiskAnalyst points out a notable decline in backlog and a lower expected conversion of that backlog into revenue, reducing revenue visibility and raising execution risk.
Competition RiskAnalyst warns that increased competition from well-capitalized new entrants and established rivals like Roche could erode market share and force pricing or spending actions that pressure margins.
Platform Transition HeadwindsAnalyst highlights falling placements of legacy instruments and weaker consumables pull-through on older platforms, which could weigh on future consumables revenue as installations are slower to convert.
Illumina News
ILMN FAQ
What was Illumina’s price range in the past 12 months?
Illumina lowest stock price was $68.70 and its highest was $151.34 in the past 12 months.
What is Illumina’s market cap?
Illumina’s market cap is $22.20B.
When is Illumina’s upcoming earnings report date?
Illumina’s upcoming earnings report date is Feb 05, 2026 which is in 18 days.
How were Illumina’s earnings last quarter?
Illumina released its earnings results on Oct 30, 2025. The company reported $1.34 earnings per share for the quarter, beating the consensus estimate of $1.168 by $0.172.
Is Illumina overvalued?
According to Wall Street analysts Illumina’s price is currently Overvalued.
Does Illumina pay dividends?
Illumina does not currently pay dividends.
What is Illumina’s EPS estimate?
Illumina’s EPS estimate is 1.22.
How many shares outstanding does Illumina have?
Illumina has 152,800,000 shares outstanding.
What happened to Illumina’s price movement after its last earnings report?
Illumina reported an EPS of $1.34 in its last earnings report, beating expectations of $1.168. Following the earnings report the stock price went up 24.775%.
Which hedge fund is a major shareholder of Illumina?
Currently, no hedge funds are holding shares in ILMN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Illumina Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$124.12 (-12.38% Downside)
$124.12 (-12.38% Downside)
Blogger Sentiment
Bullish
ILMN Sentiment 80%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 10.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $93.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.4%
Last 30 Days ▲ 8.8%
Last 30 Days ▲ 8.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
3.11%
12-Months-Change
Fundamentals
Return on Equity
31.20%
Trailing 12-Months
Asset Growth
2.71%
Trailing 12-Months
Company Description
Illumina
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. The company was incorporated in 1998 and is based in San Diego, California.
ILMN Company Deck
ILMN Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in clinical markets and the NovaSeq X transition, with revenue and earnings exceeding expectations. However, challenges in research markets and ongoing issues in China present hurdles. Despite these challenges, the company remains optimistic about its strategic initiatives and future growth.View all ILMN earnings summariesILMN Revenue Breakdown
72.16% Consumables
11.46% Instruments
16.38% Service and other revenue
ILMN Stock 12 Month Forecast
Average Price Target
$124.12
▼(-12.38% Downside)
Technical Analysis
Ownership Overview
Currently, No data available
---